Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in moderate-to-severe atopic dermatitis
NCT01859988Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2013
- Primary completion
- May 2014
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of dupilumab in atopic dermatitis (AD), sponsored by Regeneron Pharmaceuticals. Started May 2013; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT01859988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01859988.